These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
4. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. Campbell KR; Ohman EM; Cantor W; Lincoff AM Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178 [TBL] [Abstract][Full Text] [Related]
5. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
6. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466 [TBL] [Abstract][Full Text] [Related]
7. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
8. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. De Luca G; Savonitto S; van't Hof AW; Suryapranata H Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890 [TBL] [Abstract][Full Text] [Related]
9. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt DL; Topol EJ JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650 [TBL] [Abstract][Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258 [TBL] [Abstract][Full Text] [Related]
11. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. Montalescot G; Borentain M; Payot L; Collet JP; Thomas D JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. Vorchheimer DA; Badimon JJ; Fuster V JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552 [TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Roffi M; Chew DP; Mukherjee D; Bhatt DL; White JA; Moliterno DJ; Heeschen C; Hamm CW; Robbins MA; Kleiman NS; Théroux P; White HD; Topol EJ Eur Heart J; 2002 Sep; 23(18):1441-8. PubMed ID: 12208224 [TBL] [Abstract][Full Text] [Related]
16. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes. Bosanquet N; Jönsson B; Fox KA Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436 [TBL] [Abstract][Full Text] [Related]
17. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E; N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424 [TBL] [Abstract][Full Text] [Related]
19. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]